Physician profile
Venkata Muddana
NPI 1912055237
$11,633.77
in general payments reported to CMS, 2019-2025
20 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $109 · 2021: $67.62 · 2022: $421 · 2023: $3,065 · 2024: $5,461 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,700 · Food and Beverage: $2,635 · Honoraria: $2,500 · Travel and Lodging: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,700.00 |
| Food and Beverage | $2,635.28 |
| Honoraria | $2,500.00 |
| Travel and Lodging | $1,013.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumendi LLC | $4,780.21 | 2020-2024 | |
| Erbe USA INC | $2,700.00 | 2023 | Erbe Vio3 |
| Apollo Endosurgery US INC | $974.98 | 2019 | |
| Olympus America INC. | $730.48 | 2021-2025 | Single Use Electrosurgical Knife Kd-655, Endoclot Phs, Gastrointestinal Videoscope |
| Boston Scientific Corporation | $557.15 | 2019-2025 | General - Therapies, Axonics, Axios |
| Takeda Pharmaceuticals U.S.A., INC. | $381.71 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $362.64 | 2020-2025 | |
| Steris Corporation | $289.02 | 2024-2025 | |
| Cook Medical LLC | $270.53 | 2020-2025 | Echotip Insight |
| Medtronic, INC. | $142.23 | 2022-2023 | Pillcam |
| Qol Medical, LLC | $98.91 | 2025 | Sucraid |
| Gilead Sciences, INC. | $96.26 | 2019 | |
| Genzyme Corporation | $73.01 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.02 | 2023-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $34.92 | 2025 | Zenpep |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $29.46 | 2024 | Injectafer |
| Tersera Therapeutics LLC | $19.83 | 2025 | Xermelo |
| Pfizer INC. | $15.20 | 2025 | |
| Novo Nordisk INC | $13.51 | 2024 | Wegovy |
| Phathom Pharmaceuticals, INC. | $10.70 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkata Muddana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.